Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

December 27, 2023

https://www.globenewswire.com/news-release/2023/12/26/2801088/0/en/Oncternal-Therapeutics-Updates-the-Status-of-its-Phase-1-2-Study-of-ONCT-808-a-ROR1-Targeting-Autologous-CAR-T-in-Patients-with-Relapsed-or-Refractory-Aggressive-B-cell-Lymphoma.html

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.

Read more at globenewswire.com

Related news for (ONCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.